Purvish M. Parikh

6.5k total citations · 3 hit papers
160 papers, 4.4k citations indexed

About

Purvish M. Parikh is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Hematology. According to data from OpenAlex, Purvish M. Parikh has authored 160 papers receiving a total of 4.4k indexed citations (citations by other indexed papers that have themselves been cited), including 51 papers in Oncology, 32 papers in Pulmonary and Respiratory Medicine and 28 papers in Hematology. Recurrent topics in Purvish M. Parikh's work include Chronic Lymphocytic Leukemia Research (18 papers), Acute Lymphoblastic Leukemia research (14 papers) and Breast Cancer Treatment Studies (13 papers). Purvish M. Parikh is often cited by papers focused on Chronic Lymphocytic Leukemia Research (18 papers), Acute Lymphoblastic Leukemia research (14 papers) and Breast Cancer Treatment Studies (13 papers). Purvish M. Parikh collaborates with scholars based in India, Pakistan and United States. Purvish M. Parikh's co-authors include Alex Y. Chang, Nick Thatcher, José Rodrigues Pereira, Tudor–Eliade Ciuleanu, Joachim von Pawel, Sumitra Thongprasert, E.H. Tan, Kristine Pemberton, Venice Archer and Kevin Carroll and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Purvish M. Parikh

149 papers receiving 4.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

2005 1.7k citations Nick Thatcher, Alex Y. Chang et al. profile →
Molecular Predictors of Outcome With Gefitinib in a Phase III Placebo-Controlled Study in Advanced Non–Small-Cell Lung Cancer

2006 570 citations Nick Thatcher, Alex Y. Chang et al. profile →
Lung cancer immunotherapy: progress, pitfalls, and promises

2023 568 citations Aritraa Lahiri, Pravin D. Potdar et al. Molecular Cancer profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Purvish M. Parikh India	21	2.6k	2.6k	952	587	302	160	4.4k
Antoinette J. Wozniak United States	31	3.1k 1.2×	2.3k 0.9×	988 1.0×	421 0.7×	378 1.3×	102	4.6k
Siow Ming Lee United Kingdom	38	2.4k 0.9×	2.0k 0.8×	1.6k 1.7×	547 0.9×	319 1.1×	171	4.9k
John Grous United States	12	4.1k 1.6×	2.6k 1.0×	966 1.0×	431 0.7×	321 1.1×	23	5.1k
Pilar Garrido Spain	31	2.1k 0.8×	1.9k 0.7×	909 1.0×	610 1.0×	402 1.3×	291	3.9k
Petr Zatloukal Czechia	33	3.7k 1.4×	3.4k 1.3×	1.6k 1.7×	603 1.0×	273 0.9×	87	5.7k
Kirsten B. Goldberg United States	39	2.7k 1.0×	1.3k 0.5×	979 1.0×	711 1.2×	431 1.4×	66	4.5k
James Stevenson United States	38	3.5k 1.4×	2.8k 1.1×	1.2k 1.3×	546 0.9×	340 1.1×	137	5.9k
Mark Vincent Canada	38	3.8k 1.4×	3.7k 1.4×	1.5k 1.6×	723 1.2×	656 2.2×	171	6.5k
Shenghui Tang United States	39	2.9k 1.1×	1.8k 0.7×	1.2k 1.2×	855 1.5×	448 1.5×	116	5.3k
Nick Thatcher United Kingdom	34	4.0k 1.5×	3.9k 1.5×	1.5k 1.6×	810 1.4×	365 1.2×	117	5.7k

Countries citing papers authored by Purvish M. Parikh

Since Specialization

Citations

This map shows the geographic impact of Purvish M. Parikh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Purvish M. Parikh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Purvish M. Parikh more than expected).

Fields of papers citing papers by Purvish M. Parikh

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Purvish M. Parikh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Purvish M. Parikh. The network helps show where Purvish M. Parikh may publish in the future.

Co-authorship network of co-authors of Purvish M. Parikh

This figure shows the co-authorship network connecting the top 25 collaborators of Purvish M. Parikh. A scholar is included among the top collaborators of Purvish M. Parikh based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Purvish M. Parikh. Purvish M. Parikh is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Parikh, Purvish M.. (2024). Artificial Intelligence: ChatGPT to Artificial Intelligence Washing. 9(1--3). 1–4.

Govil, Deepak, Vijay K. Arora, Vinod Malik, et al.. (2024). Transanal Minimally Invasive Surgery for Rectal Cancer. SHILAP Revista de lepidopterología. 13(4). 263–266. 1 indexed citations

Somashekhar, S. P., et al.. (2024). Current Status of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Colorectal Cancer (CRC). SHILAP Revista de lepidopterología. 13(4). 267–273.

Parikh, Purvish M., Anil Arora, Mandhir Kumar, et al.. (2024). Familial Polyposis and Colon Cancer. SHILAP Revista de lepidopterología. 13(4). 305–308.

Parikh, Purvish M., Akhil Kapoor, Tarini Prasad Sahoo, et al.. (2024). Consensus Guidelines for the Use of Cyclin-Dependent Kinase (CDK) 4/6 Inhibitors in the Management of Hormone Receptor Positive (HR+ve), Her2−ve Early Breast Cancer (EBC). SHILAP Revista de lepidopterología. 14(1). 45–52. 1 indexed citations

Kochhar, Rohit, Harsh Mahajan, Arun Gupta, et al.. (2024). CT and MR Imaging in Colorectal Carcinoma: A Tool for Diagnosis, Staging, Response Evaluation, and Follow-Up. SHILAP Revista de lepidopterología. 13(4). 236–240. 1 indexed citations

Parikh, Purvish M., Tarini Prasad Sahoo, Ghanashyam Biswas, et al.. (2024). Practical Consensus Guidelines for the Use of S-1 in GI Malignancies. SHILAP Revista de lepidopterología. 13(1). 77–82. 4 indexed citations

Lahiri, Aritraa, Pravin D. Potdar, Navneet Singh, et al.. (2023). Lung cancer immunotherapy: progress, pitfalls, and promises. Molecular Cancer. 22(1). 40–40. 568 indexed citations breakdown →

Tshomo, Ugyen, et al.. (2023). Cervical Cancer HPV Vaccination and Bhutan. SHILAP Revista de lepidopterología. 12(1). 41–43. 3 indexed citations

10.

Parikh, Purvish M.. (2023). Ayurvedic Doctors Cannot Prescribe Allopathic Medicines—National Consumer Dispute Redressal Commission Judgement. SHILAP Revista de lepidopterología. 12(2). 100–103.

11.

Parikh, Purvish M., Govind Babu, Randeep Singh, et al.. (2023). Consensus guidelines for the management of HR-positive HER2/neu negative early breast cancer in India, SAARC region and other LMIC by DELPHI survey method. BMC Cancer. 23(1). 714–714. 3 indexed citations

12.

Bhat, Satish S., et al.. (2021). Vulture journalism in medical reporting – Has the Lancet become a rag newspaper?. Indian Journal of Medical Sciences. 73. 4–7.

13.

Parikh, Purvish M., et al.. (2020). Lessons from the COVID-19 pandemic for virtual academic activities. Indian Journal of Medical Sciences. 72. 125–126. 1 indexed citations

14.

Agarwal, J.P., Tapas K. Das Gupta, Purvish M. Parikh, et al.. (2008). Second primary small cell carcinoma of the trachea in a breast cancer survivor: a case report and literature review. British Journal of Radiology. 81(964). e120–e122. 8 indexed citations

15.

Karanth, Narayan, et al.. (2008). Mediastinal lymphadenopathy in a patient with previously treated T‐cell acute lymphoblastic leukaemia. The Medical Journal of Australia. 188(2). 117–118. 2 indexed citations

16.

Banavali, Shripad, et al.. (2008). RUNX1 ABERRATIONS IN ETV6/RUNX1-POSITIVE AND ETV6/RUNX1-NEGATIVE PATIENTS: Its Hemato-Pathological and Prognostic Significance in a Large Cohort (619 Cases) of ALL. Pediatric Hematology and Oncology. 25(6). 582–597. 13 indexed citations

17.

Chang, Alex Y., Purvish M. Parikh, Sumitra Thongprasert, et al.. (2006). Gefitinib (IRESSA) in Patients of Asian Origin with Refractory Advanced Non-small Cell Lung Cancer: Subset Analysis from the ISEL Study. Journal of Thoracic Oncology. 1(8). 847–855. 144 indexed citations

18.

Parikh, Purvish M., et al.. (2006). Newer Diagnostic Methods in Oncology. Medical Journal Armed Forces India. 62(2). 162–168. 9 indexed citations

19.

Deshmukh, Chetan, et al.. (2003). Neoadjuvant Chemotherapy with Ifosfamide and Cisplatin Combination in Advanced Head and Neck Cancer: A Retrospective Analysis of 519 Patients: A Single Institution Experience. Medical Oncology. 20(1). 1–6. 3 indexed citations

20.

Parikh, Purvish M., Bishan S. Charak, Shripad Banavali, et al.. (1988). Treatment of askin rosai tumor—need for a more aggressive approach. Journal of Surgical Oncology. 39(2). 126–128. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact